| Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Mar'18 |
|---|---|---|---|---|---|---|
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | ||||||
131,921 | 67,796 | 62,360 | 85,353 | - | - | 7,194 |
Cash | ||||||
- | - | - | - | 95,613 | 1,659 | - |
Restricted cash | ||||||
243 | 243 | 243 | 243 | 244 | - | - |
Prepaid expenses and other current assets | ||||||
10,182 | 8,823 | 8,416 | 12,914 | 15,140 | 11,757 | 5,196 |
Due from Sumitovant Pharma Ltd. | ||||||
111 | - | - | - | - | - | - |
Deferred initial public offering costs | ||||||
- | - | - | - | - | 2,201 | - |
Total current assets | ||||||
142,457 | 76,862 | 71,019 | 98,510 | 110,997 | 15,617 | 12,390 |
Furniture and equipment, net | ||||||
1,241 | 1,226 | 1,203 | 923 | 571 | 587 | 510 |
Operating lease right-of-use assets | ||||||
3,219 | 3,301 | 3,386 | - | - | - | - |
Restricted cash, net of current portion | ||||||
623 | 623 | 623 | 600 | 600 | - | - |
Other assets | ||||||
11 | 16 | 21 | 88 | 84 | 84 | 84 |
Total assets | ||||||
147,551 | 82,028 | 76,252 | 100,121 | 112,252 | 16,288 | 12,984 |
Liabilities and Shareholders' (Deficit) Equity | ||||||
Current liabilities: | ||||||
Accounts payable | ||||||
2,388 | 1,567 | 2,971 | 1,925 | 3,696 | 5,084 | 833 |
Accrued expenses | ||||||
14,701 | 9,590 | 8,287 | 9,877 | 6,365 | 9,875 | 3,595 |
Due to Roivant Sciences Ltd. | ||||||
7 | 133 | 97 | 15 | 33 | 8,056 | 1,482 |
Interest payable | ||||||
343 | - | - | - | - | - | - |
Current portion of long-term debt | ||||||
43,760 | 10 | - | - | - | - | - |
Current portion of operating lease liabilities | ||||||
335 | 265 | 92 | - | - | - | - |
Total current liabilities | ||||||
61,534 | 11,565 | 11,447 | 11,817 | - | - | 5,910 |
Long-term debt, net of current portion | ||||||
87,287 | 43,438 | 13,728 | 13,534 | - | - | - |
Operating lease liabilities, net of current portion | ||||||
3,179 | 3,269 | 3,357 | - | - | - | - |
Total liabilities | ||||||
152,000 | 58,272 | 28,532 | 25,351 | 10,094 | 23,015 | 5,910 |
Commitments and contingencies (Note 9) | ||||||
- | - | - | - | - | 0 | - |
Shareholders' (deficit) equity | ||||||
Common shares, par value $0.000037453 per share, 267,001,308 shares authorized, 30,519,688 and 30,322,911 issued and outstanding at December 31, 2019 and March 31, 2019, respectively | ||||||
1 | 1 | 1 | 1 | 1 | 1 | 1 |
Common shares subscribed | ||||||
1 | 1 | 1 | 1 | 1 | 1 | 1 |
Shareholder receivable | ||||||
- | - | - | - | - | 1,310 | 1,310 |
Accumulated other comprehensive income | ||||||
394 | 365 | 457 | 269 | 320 | 104 | 7 |
Additional paid-in capital | ||||||
266,173 | 253,148 | 251,279 | 250,032 | 248,401 | 114,601 | 72,562 |
Accumulated deficit | ||||||
-271,016 | -229,757 | -204,016 | -175,531 | -146,563 | -120,122 | -64,185 |
Total shareholders' (deficit) equity | ||||||
-4,449 | 23,756 | 47,720 | 74,770 | 102,158 | -6,727 | 7,074 |
Total liabilities and shareholders' (deficit) equity | ||||||
147,551 | 82,028 | 76,252 | 100,121 | 112,252 | 16,288 | 12,984 |